Home/Science 37/Jonathan Cotliar, MD

Jonathan Cotliar, MD

Chief Scientific Officer & Co-Founder

Therapeutic Areas

Drug	Indication	Phase
Fragile X Syndrome Trial	Fragile X Syndrome	Phase 3
Narcolepsy Study	Narcolepsy	Phase 4
Asthma Trial	Asthma	Phase 3
COVID-19 Prophylaxis Trial	COVID-19 Prophylaxis	Phase 3
Colorectal Cancer Prevention Trial	Colorectal Cancer Prevention	Pivotal
Primary Biliary Cholangitis (PBC) Trial	Primary Biliary Cholangitis	Phase 3
Vascular Ehlers-Danlos Syndrome Trial	Vascular Ehlers-Danlos Syndrome	Phase 3
Cholestatic Pruritus Trial	Cholestatic Pruritus	Phase 2